153 related articles for article (PubMed ID: 14969343)
1. DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.
Seo J; Lee HS; Lee M; Kim M; Shin CG
Arch Pharm Res; 2004 Jan; 27(1):77-82. PubMed ID: 14969343
[TBL] [Abstract][Full Text] [Related]
2. Patterns of strongly protein-associated simian virus 40 DNA replication intermediates resulting from exposures to specific topoisomerase poisons.
Shin CG; Snapka RM
Biochemistry; 1990 Dec; 29(49):10934-9. PubMed ID: 2176889
[TBL] [Abstract][Full Text] [Related]
3. Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors.
Permana PA; Snapka RM; Shen LL; Chu DT; Clement JJ; Plattner JJ
Biochemistry; 1994 Sep; 33(37):11333-9. PubMed ID: 7727384
[TBL] [Abstract][Full Text] [Related]
4. Effect of ICRF-193, a novel DNA topoisomerase II inhibitor, on simian virus 40 DNA and chromosome replication in vitro.
Ishimi Y; Ishida R; Andoh T
Mol Cell Biol; 1992 Sep; 12(9):4007-14. PubMed ID: 1324412
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of topoisomerase I or II may lead to recombination or to aberrant replication termination on both SV40 and yeast 2 micron DNA.
Levac P; Moss T
Chromosoma; 1996 Oct; 105(4):250-60. PubMed ID: 8854885
[TBL] [Abstract][Full Text] [Related]
7. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288).
Lothstein L; Suttle DP; Roaten JB; Koseki Y; Israel M; Sweatman TW
Biochem Pharmacol; 2000 Dec; 60(11):1621-8. PubMed ID: 11077044
[TBL] [Abstract][Full Text] [Related]
8. Swiveling and decatenation of replicating simian virus 40 genomes in vivo.
Snapka RM; Powelson MA; Strayer JM
Mol Cell Biol; 1988 Feb; 8(2):515-21. PubMed ID: 2832724
[TBL] [Abstract][Full Text] [Related]
9. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
Smith PJ; Bell SM; Dee A; Sykes H
Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
[TBL] [Abstract][Full Text] [Related]
10. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
11. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Ellis AL; Nowak B; Plunkett W; Zwelling LA
Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase inhibitors can selectively interfere with different stages of simian virus 40 DNA replication.
Snapka RM
NCI Monogr; 1987; (4):55-60. PubMed ID: 2819732
[TBL] [Abstract][Full Text] [Related]
13. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
14. Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Wong ML; Hsu MT
J Virol; 1990 Feb; 64(2):691-9. PubMed ID: 2153235
[TBL] [Abstract][Full Text] [Related]
15. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.
Capranico G; Kohn KW; Pommier Y
Nucleic Acids Res; 1990 Nov; 18(22):6611-9. PubMed ID: 2174543
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of topoisomerase II by liriodenine.
Woo SH; Reynolds MC; Sun NJ; Cassady JM; Snapka RM
Biochem Pharmacol; 1997 Aug; 54(4):467-73. PubMed ID: 9313773
[TBL] [Abstract][Full Text] [Related]
17. An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.
Hong G; Kreuzer KN
Mol Cell Biol; 2000 Jan; 20(2):594-603. PubMed ID: 10611238
[TBL] [Abstract][Full Text] [Related]
18. Biological characterization of MLN944: a potent DNA binding agent.
Sappal DS; McClendon AK; Fleming JA; Thoroddsen V; Connolly K; Reimer C; Blackman RK; Bulawa CE; Osheroff N; Charlton P; Rudolph-Owen LA
Mol Cancer Ther; 2004 Jan; 3(1):47-58. PubMed ID: 14749475
[TBL] [Abstract][Full Text] [Related]
19. Cross-sensitivity to topoisomerase II inhibitors in cytotoxic drug-hypersensitive Chinese hamster ovary cell lines.
Robson CN; Hoban PR; Harris AL; Hickson ID
Cancer Res; 1987 Mar; 47(6):1560-5. PubMed ID: 2434220
[TBL] [Abstract][Full Text] [Related]
20. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells.
Takano H; Kohno K; Ono M; Uchida Y; Kuwano M
Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
